ERBB2 and breast carcinoma: Our study validated the existence of activated ERRα-CCNE1 signaling pathway in HER2-positive breast cancer cell line–SK-BR-3, which suggests that the dysexpression of ERRα may be one of the factors contributing to the over-expression of CCNE1 in breast tumor.